Hovilpri (pritelivir)
AiCuris Anti-infective Cures
ApprovedOct 9, 2026
Marketer take
A niche launch for refractory HSV in immunocompromised adults, so transplant and oncology-center ID specialists and hospital formulary committees are the core audience.
- Sponsor company
- AiCuris Anti-infective Cures
- Indication
- To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- Oct 9, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?